Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arrowhead Pharmaceuticals' SEC filings reveal how a clinical-stage biopharmaceutical company allocates capital across competing therapeutic programs while managing the inherent uncertainty of drug development. For biotech investors, these documents contain critical disclosures that quarterly earnings calls often gloss over.
Form 10-K annual reports detail which RNAi programs receive priority funding and how clinical trial expenses distribute across the pipeline. The Risk Factors section candidly describes regulatory hurdles, competitive threats from other gene silencing approaches, and dependencies on specific manufacturing partners. Arrowhead's 10-K breaks down research and development spending by therapeutic area, letting you assess whether resources align with stated strategic priorities. Patent expiration timelines and intellectual property litigation also surface here.
Form 10-Q quarterly reports track cash burn rates and runway—essential metrics for a company not yet generating product revenue. Clinical trial updates embedded in quarterly filings sometimes provide more technical detail than press releases, including patient enrollment rates, protocol amendments, and reasons for trial delays. Changes in collaboration revenue from quarter to quarter signal whether partners are hitting milestones or abandoning programs.
Form 8-K current reports announce material events including partnership agreements with detailed financial terms, clinical trial results that move stock prices, and FDA communications regarding regulatory pathways. For Arrowhead, 8-K filings often disclose the specific financial structure of collaborations—upfront payments, milestone schedules, and royalty percentages—that determine future revenue potential.
Form 4 insider transaction filings show when executives and directors buy or sell shares. In clinical-stage biotech, insider selling before trial readouts or insider buying during market downturns can provide context on management's confidence, though these transactions require careful interpretation alongside other factors.
DEF 14A proxy statements reveal executive compensation structures, including how much pay ties to clinical milestones versus stock performance. For a company where success depends on navigating decade-long development timelines, understanding whether incentives reward long-term scientific progress or short-term stock appreciation matters.
Our AI summaries extract the biotech-specific disclosures that matter most: pipeline prioritization decisions, clinical trial enrollment challenges, manufacturing dependencies, partnership economics, and intellectual property risks. Save hours navigating complex regulatory language.
Arrowhead Pharmaceuticals director reports stock grant. A director of Arrowhead Pharmaceuticals, Inc. reported receiving 7,819 shares of common stock on 12/16/2025 at a price of $0. These shares represent restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date.
After this grant, the director beneficially owns 64,930 shares of Arrowhead common stock in direct ownership. The filing indicates it was made by a single reporting person serving as a director of the company.
Arrowhead Pharmaceuticals reported insider equity activity by its chief executive officer and director in December 2025. On December 12, 2025, he received 180,000 shares underlying restricted stock units, which will vest in four equal annual installments.
On December 15 and 16, 2025, he sold multiple blocks of common stock, including 100,532 shares at a weighted average price of $68.67 and 21,321 shares at $69.28, exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. After these transactions, he beneficially owned 3,916,957 Arrowhead common shares, which include previously reported shares underlying restricted stock units that remain subject to vesting conditions.
Arrowhead Pharmaceuticals (ARWR) files its annual report describing a transition from a pure R&D biotech to a commercial-stage RNA interference company. The business centers on its proprietary TRiM platform, which uses targeted siRNA to silence disease-causing genes across multiple tissues.
A major milestone is the 2025 FDA approval and U.S. commercial launch of REDEMPLO (plozasiran) for adults with Familial Chylomicronemia Syndrome, the first and only FDA‑approved siRNA studied in both genetically confirmed and clinically diagnosed FCS patients. The company is running fully enrolled Phase 3 studies in severe hypertriglyceridemia and plans a supplemental NDA in 2026.
Arrowhead reports 18 company-discovered drug candidates in clinical trials, spanning cardiovascular, liver, obesity, renal, pulmonary, CNS and rare neuromuscular diseases, plus a discovery pipeline. It highlights extensive collaborations with GSK, Takeda, Amgen, Sarepta and Novartis that can generate milestones and royalties, and an IP estate of about 643 issued patents and roughly 833 pending applications worldwide.
Arrowhead Pharmaceuticals, Inc. reported that it has announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. The announcement was made on November 25, 2025.
The company provided these results in a press release that is included as Exhibit 99.1, with an additional Exhibit 104 covering the interactive data for the cover page. The report was signed on behalf of the company by Chief Financial Officer Daniel Apel.
Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare lipid disorder. This marks a significant regulatory milestone for the company, adding an FDA‑approved therapy to its portfolio. Arrowhead also held a conference call to discuss the approval and provided a detailed press release and slide presentation as exhibits to the report.
Arrowhead Pharmaceuticals amended its annual report to disclose a major collaboration with Sarepta Therapeutics and results for fiscal 2024. The company expects to receive
Pipeline and platform highlights include advancement of multiple RNAi programs (ARO-INHBE, ARO-ALK7, ARO-DM1, ARO-C3, ARO-CFB, ARO-RAGE and others) with Phase 1/2a filings and Phase 2/3 results for cardiometabolic candidates. Financially, fiscal 2024 revenue was
Form 144 notice: The filer proposes to sell 20,000 shares of common stock through Merrill Lynch on 10/01/2025 with an aggregate market value of $700,014.67. The issuer has 138,257,550 shares outstanding. The securities to be sold were acquired as compensation in multiple grants between 01/04/2022 and 01/04/2025 totaling 63,232 shares granted across six dated entries. In the past three months the reporting person sold 40,000 shares on four dates (08/13/2025, 08/15/2025, 09/02/2025, 09/12/2025) generating aggregate gross proceeds of $1,024,880.20. The filer attests they have no undisclosed material adverse information and includes the standard Rule 144 representations.
James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported a sale of 15,000 shares of common stock on 09/12/2025 at $30 per share under a pre-established 10b5-1 trading plan. After the transaction he beneficially owns 232,122 shares, which includes previously reported shares underlying restricted stock units, some of which remain subject to vesting.
The Form 4 discloses the transaction and the reporting person’s relationship to the issuer (Officer and Director). The filing clarifies the sale was pursuant to the trading plan and that a portion of the reported holdings represents unvested restricted stock units.
Arrowhead Research Corporation (ARWR) filed an 8-K reporting a material event that primarily contains forward-looking statement disclosures and a brief litigation update. The company states it intends to vigorously pursue its claims in an ongoing lawsuit and refers to planned commercialization efforts for its investigational drug plozasiran. The filing cites uncertainties tied to the Ionis letter, the validity and enforceability of the '333 Patent, the company’s broader patent portfolio, and the outcome of the lawsuit. It emphasizes that forward-looking statements are based on current expectations and that actual results may differ materially due to risks described in prior SEC filings.
Insider sale under 10b5-1 plan: James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), reported a sale of 15,000 shares of common stock executed pursuant to a Rule 10b5-1 trading plan at a price of $25 per share, reducing his reported beneficial ownership to 247,122 shares. The filing notes that the remaining reported shares include previously disclosed restricted stock units, some of which remain subject to vesting conditions. No options, warrants, or other derivative transactions are reported.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
